US20150024064A1 - pKa Buffered Vitamin C Composition and Method - Google Patents
pKa Buffered Vitamin C Composition and Method Download PDFInfo
- Publication number
- US20150024064A1 US20150024064A1 US14/506,262 US201414506262A US2015024064A1 US 20150024064 A1 US20150024064 A1 US 20150024064A1 US 201414506262 A US201414506262 A US 201414506262A US 2015024064 A1 US2015024064 A1 US 2015024064A1
- Authority
- US
- United States
- Prior art keywords
- composition
- vitamin
- weight
- alkalizing
- pka
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 219
- 239000000203 mixture Substances 0.000 title claims abstract description 144
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 79
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 79
- 239000011718 vitamin C Substances 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 96
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 48
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 32
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 32
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 30
- 235000010376 calcium ascorbate Nutrition 0.000 claims abstract description 11
- 229940047036 calcium ascorbate Drugs 0.000 claims abstract description 11
- 239000011692 calcium ascorbate Substances 0.000 claims abstract description 11
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims abstract description 11
- 210000002784 stomach Anatomy 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract description 4
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 4
- 239000010452 phosphate Substances 0.000 claims abstract description 4
- 230000002459 sustained effect Effects 0.000 claims abstract description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 114
- 230000003113 alkalizing effect Effects 0.000 claims description 48
- 239000001506 calcium phosphate Substances 0.000 claims description 39
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 32
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 32
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 32
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 32
- 244000215068 Acacia senegal Species 0.000 claims description 30
- 235000006491 Acacia senegal Nutrition 0.000 claims description 30
- 229920000084 Gum arabic Polymers 0.000 claims description 30
- 235000010489 acacia gum Nutrition 0.000 claims description 30
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 24
- 239000000347 magnesium hydroxide Substances 0.000 claims description 24
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 24
- 239000011736 potassium bicarbonate Substances 0.000 claims description 15
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 15
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 15
- 229940094025 potassium bicarbonate Drugs 0.000 claims description 15
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 7
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 7
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 7
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 2
- 229960003563 calcium carbonate Drugs 0.000 claims 1
- 229940093932 potassium hydroxide Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 17
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- 239000011777 magnesium Substances 0.000 abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000011591 potassium Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 32
- 238000012360 testing method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- -1 ascorbate ion Chemical class 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Definitions
- Vitamin C is a common dietary supplement typically taken in the form of pills or capsules to supplement the human diet. Taken as a supplement from fifty milligrams to 5,000 milligrams daily, vitamin C can support improved health and can improve the immune system. It is an important nutrient to help neutralize free radicals and promote maximum intercellular communication. However, it has to be consumed or replenished regularly since it is not retained in the body.
- vitamin C taken orally in supplements causes discomfort to many users. This is because the vitamin C reacts with the hydrochloric acid (HCL) in the user's stomach thereby generating excessive stomach acids. Specifically, vitamin C is very acidic with a pH of 4.2; and people with acid problems (44% of the U.S. population has either acid reflux or occasional heartburn) cannot tolerate this pH level. Although there are a number of common buffering tablets containing carbonate and bicarbonates that can be consumed with vitamin C to relieve this gastrointestinal stress, none of them is formulated to aid GERD reduction and the absorption and retention of the vitamin C.
- the inventive composition when orally ingested is not only gentle to the user's stomach, but can also help replace calcium that the vitamin C might remove from the user's body.
- a pKa buffered vitamin C composition which includes a base alkalizer composition mixed with vitamin C (calcium ascorbate or ascorbic acid).
- the base alkalizer composition preferably can be approximately 24% to 40% by weight and the ascorbic acid or calcium ascorbate can be preferably approximately 76% to 60%.
- the base alkalizer composition can preferably include the combination of a calcium carbonate carrier which acts as a mild alkalizer, a hydroxide (magnesium or potassium) which acts as a fast alkalizer, and a phosphate (dicalcium or tricalcium) which acts as a moderate alkalizer and which also maintains the pH fairly stable over an about twenty to forty minute time period.
- a calcium carbonate carrier which acts as a mild alkalizer
- a hydroxide magnesium or potassium
- phosphate diicalcium or tricalcium
- the pKa buffered vitamin C composition comprises an alkalizing base composition which includes (or consists of or consists essentially of) calcium carbonate, magnesium hydroxide, DC ascorbic acid, a binder (gum acacia), potassium hydroxide and dicalcium phosphate; and a vitamin C source mixed with the alkalizing base composition.
- the pKa buffered vitamin C composition comprises an alkalizing base composition which includes (or consists of or consists essentially of) calcium carbonate, potassium hydroxide, a binder (gum acacia), potassium bicarbonate, dicalcium phosphate and tricalcium phosphate; and a vitamin C source mixed with the alkalizing base composition.
- the pKa buffered vitamin C composition comprises an alkalizing base composition which includes (or consists of or consists essentially of) calcium carbonate, potassium hydroxide, potassium carbonate and dicalcium phosphate; and a vitamin C source mixed with the alkalizing base composition.
- the alkalizing composition of the vitamin C composition may comprise any one or a combination of the following: sodium hydroxide, magnesium hydroxide, tricalcium phosphate, a vitamin, such as ascorbic acid and/or vitamin D 3 , and a binder such as gum acacia.
- the present invention includes methods (and compositions) for buffering high acid nutraceuticals, specifically (but not limited to) vitamin C to be taken orally as dietary supplements.
- FIG. 1 shows the test results for formulation #1.
- FIG. 2 shows the test results for formulation #2.
- FIG. 3 shows the test results for formulation #3.
- FIG. 4 shows the test results for formulation #4.
- FIG. 5 shows the test results for formulation #5.
- FIG. 6 shows the test results for formulation #6.
- FIG. 7 shows the test results for formulation #7.
- FIG. 8 shows the test results for formulation #8.
- FIG. 9 shows the test results for formulation #9.
- FIG. 10 shows the test results for formulation #10.
- FIG. 11 shows the test results for formulation #11.
- FIG. 12 shows the test results for formulation #12.
- a pKa buffered vitamin C composition of the present invention is formed by mixing, such as in a ribbon blender, an alkalizing base composition (numerous formulations of which are disclosed in detail in this disclosure) and vitamin C.
- the vitamin C can be powder or compressible-granular calcium ascorbate or ascorbic acid.
- the base alkalizer composition can be approximately 24% to 40% (or approximately 24%) by weight and the ascorbic acid or calcium ascorbate approximately 60% to 76% (or approximately 76%) of the vitamin C composition.
- the vitamin C composition thereby formed is packaged, for example, in fifty or twenty-five kilogram packages. The packages are delivered to a tablet or capsule manufacturer who puts the composition into tablet or capsule form as would be known and in sizes as would also be known by those skilled in the art.
- a minimum of 240 milligrams of base composition to 500 milligrams of vitamin C may be included. While a preferred embodiment is 500 milligrams of vitamin C, it can be buffered just as well pursuant to this invention at 200 milligrams of vitamin C. Further, smaller tablets of 80 milligrams of base to 200 milligrams of vitamin C are also within the scope of the invention.
- the alkalizing compositions may be produced as a granulated, agglomerate compound by milling, blending and spray drying the ingredients in a Shugi agglomerating system.
- the Shugi agglomerating system is a commercially available system that has been designed to agglomerate minerals to USP and pharmaceutical standards. It is designed to properly mix and agglomerate various ingredients with different molecular weights into a uniform granule.
- the ingredients of the alkalizing composition can be first milled to a fine powder.
- the fine powder is then heated to thirty degrees to thirty-nine degrees Centigrade and pressure sprayed into an environment having a relative humidity of from about 9.0% to about 15.0%.
- the fine powder is then sprayed with a solution of gum acacia to achieve a uniform granule that is free-flowing, non-dusting, and highly compressible. Gum acacia aids in providing uniform finished granules.
- the resulting granulated alkalizing compositions can have a pH in the range of from about 5.0 to about 13.0, from about 6.5 to about 11.5, or from about 8.0 to about 10.0.
- alkalizing base compositions are suitable for use in the formulations and methods disclosed herein:
- Formulation #1 Ingredients % by weight calcium carbonate 79.08% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99 dicalcium phosphate 1.40
- the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium hydroxide; and from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight dicalcium phosphate.
- Formulation #2 Ingredients % by weight calcium carbonate 84.00% potassium hydroxide 4.50 gum acacia 4.50 potassium bicarbonate 2.90 dicalcium phosphate 2.90 tricalcium phosphate 1.20
- the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 75% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight dicalcium phosphate; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight tricalcium phosphate; and from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium bicarbonate; and from about 0.01% to about 10%, from 0.01% to about 8%, from 0.01% to about 6%, or from about 1.0% to about 5% by weight gum acacia.
- Formulation #3 Ingredients % by weight calcium carbonate 88.08% potassium hydroxide 6.00 potassium bicarbonate 4.00 dicalcium phosphate 1.92
- the alkalizing composition comprises: from about 50% to about 99%, from about 60% to about 95%, or from about 70% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 2% to about 8%, or from about 4% to about 7% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium bicarbonate; and from about 0.01% to about 5%, from about 0.01% to about 4%, or from about 0.01% to about 3% by weight dicalcium phosphate.
- Formulation #4 Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99
- the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia, and from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium hydroxide.
- Formulation #5 Ingredients % by weight calcium carbonate 82.00% sodium hydroxide 7.50 dicalcium phosphate 2.00 potassium hydroxide 2.05 potassium bicarbonate 1.65 gum acacia 4.80
- Formulation #6 Ingredients % by weight calcium carbonate 82.00% sodium hydroxide 7.50 dicalcium phosphate 2.00 potassium hydroxide 2.00 potassium bicarbonate 3.00 gum acacia 4.00
- the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 2% to about 10%, or from about 5% to about 9% by weight sodium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 4% by weight dicalcium phosphate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 4% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 4% by weight potassium bicarbonate; from about 0.01% to about 10%, from about 0.1% to about 8%, or from about 0.01% to about 6% by weight gum acacia.
- Formulation #7 Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.77 potassium hydroxide 1.98
- the alkalizing composition may comprise from about 50% to about 99%, from about 60% to about 95%, or from about 70% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 4% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia; and from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium hydroxide.
- Formulation #8 Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 gum acacia 4.77 DC ascorbic acid 3.00 dicalcium phosphate 2.00 potassium hydroxide 1.98
- Formulation #9 Ingredients % by weight calcium carbonate 79.40% magnesium hydroxide 7.20 DC ascorbic acid 4.77 gum acacia 3.00 dicalcium phosphate 2.00 potassium hydroxide 1.98 potassium bicarbonate 1.65
- the alkalizing composition comprises from about 50% to about 99% by weight, from about 60% to about 95% by weight, or from about 70% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10% by weight, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 5% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight dicalcium phosphate; and from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium hydroxide.
- Formulation #10 Ingredients % by weight calcium carbonate 82.50% magnesium hydroxide 7.00 dicalcium phosphate 2.00 potassium hydroxide 2.00 potassium bicarbonate 1.50 gum acacia 5.00
- the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 5% by weight dicalcium phosphate; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium bicarbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia.
- the alkalizing composition may further comprise a vitamin, such as ascorbic acid.
- the alkalizing composition can comprise calcium carbonate, magnesium hydroxide, DC ascorbic acid, gum acacia, potassium hydroxide, and dicalcium phosphate.
- the alkalizing composition can contain vitamin D3.
- Formulation #11 Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99
- Formulation #12 Ingredients % by weight calcium carbonate 79.08% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99 dicalcium phosphate 1.40
- the alkalizing composition can comprise calcium carbonate, magnesium hydroxide, DC ascorbic acid, gum acacia, potassium hydroxide, and optionally vitamin D3.
- the present invention due to its high pKa, immediately neutralizes the stomach acid to a pH of 7.0 in one minute and a pH of 7.5 after eight minutes.
- Some people receive an added benefit because the temporary chelating of calcium supplied by the invention temporarily protects vitamin C (ascorbate ion) from oxidation to dehyroascorbic acid and subsequent rapid oxidative degradation in the duodenum. Additionally, some individuals absorb only a few milligrams of vitamin C (ascorbate) out of each gram of ascorbic acid ingested, and thus they will benefit from vitamin C chelated as calcium, magnesium or potassium ascorbate.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 11/675,062, filed on Feb. 14, 2007, which is herein incorporated by reference in its entirety.
- Vitamin C is a common dietary supplement typically taken in the form of pills or capsules to supplement the human diet. Taken as a supplement from fifty milligrams to 5,000 milligrams daily, vitamin C can support improved health and can improve the immune system. It is an important nutrient to help neutralize free radicals and promote maximum intercellular communication. However, it has to be consumed or replenished regularly since it is not retained in the body.
- Commercially available vitamin C taken orally in supplements causes discomfort to many users. This is because the vitamin C reacts with the hydrochloric acid (HCL) in the user's stomach thereby generating excessive stomach acids. Specifically, vitamin C is very acidic with a pH of 4.2; and people with acid problems (44% of the U.S. population has either acid reflux or occasional heartburn) cannot tolerate this pH level. Although there are a number of common buffering tablets containing carbonate and bicarbonates that can be consumed with vitamin C to relieve this gastrointestinal stress, none of them is formulated to aid GERD reduction and the absorption and retention of the vitamin C.
- The inventive composition when orally ingested is not only gentle to the user's stomach, but can also help replace calcium that the vitamin C might remove from the user's body.
- Specifically, disclosed herein is a pKa buffered vitamin C composition which includes a base alkalizer composition mixed with vitamin C (calcium ascorbate or ascorbic acid). The base alkalizer composition preferably can be approximately 24% to 40% by weight and the ascorbic acid or calcium ascorbate can be preferably approximately 76% to 60%. When this vitamin C composition is orally administered to an individual (in capsule or tablet form), it is expected that a rapid neutralization of stomach acid will advantageously occur followed by a sustained pH of about 6.0 to about 7.5 for an about thirty minute to two hour period. This allows the ingredients to be absorbed while preventing unpleasant reactions in the individual's stomach. The base alkalizer composition can preferably include the combination of a calcium carbonate carrier which acts as a mild alkalizer, a hydroxide (magnesium or potassium) which acts as a fast alkalizer, and a phosphate (dicalcium or tricalcium) which acts as a moderate alkalizer and which also maintains the pH fairly stable over an about twenty to forty minute time period.
- According to one embodiment of the invention, the pKa buffered vitamin C composition comprises an alkalizing base composition which includes (or consists of or consists essentially of) calcium carbonate, magnesium hydroxide, DC ascorbic acid, a binder (gum acacia), potassium hydroxide and dicalcium phosphate; and a vitamin C source mixed with the alkalizing base composition.
- According to another preferred embodiment of the invention, the pKa buffered vitamin C composition comprises an alkalizing base composition which includes (or consists of or consists essentially of) calcium carbonate, potassium hydroxide, a binder (gum acacia), potassium bicarbonate, dicalcium phosphate and tricalcium phosphate; and a vitamin C source mixed with the alkalizing base composition.
- According to a further preferred embodiment of the invention, the pKa buffered vitamin C composition comprises an alkalizing base composition which includes (or consists of or consists essentially of) calcium carbonate, potassium hydroxide, potassium carbonate and dicalcium phosphate; and a vitamin C source mixed with the alkalizing base composition.
- According to a still further preferred embodiment of the invention, the alkalizing composition of the vitamin C composition may comprise any one or a combination of the following: sodium hydroxide, magnesium hydroxide, tricalcium phosphate, a vitamin, such as ascorbic acid and/or vitamin D3, and a binder such as gum acacia.
- Even further, the present invention includes methods (and compositions) for buffering high acid nutraceuticals, specifically (but not limited to) vitamin C to be taken orally as dietary supplements.
- Other objects and advantages of the present invention will become more apparent to those persons having ordinary skill in the art to which the present invention pertains from the foregoing description taken in conjunction with the accompanying drawing.
- The drawing figures are graphs showing measurements of buffering effectiveness of the present invention over time for each of the formulations discussued in the following section of this disclosure.
-
FIG. 1 shows the test results forformulation # 1. -
FIG. 2 shows the test results forformulation # 2. -
FIG. 3 shows the test results forformulation # 3. -
FIG. 4 shows the test results forformulation # 4. -
FIG. 5 shows the test results forformulation # 5. -
FIG. 6 shows the test results forformulation # 6. -
FIG. 7 shows the test results forformulation # 7. -
FIG. 8 shows the test results forformulation # 8. -
FIG. 9 shows the test results forformulation # 9. -
FIG. 10 shows the test results forformulation # 10. -
FIG. 11 shows the test results forformulation # 11. -
FIG. 12 shows the test results forformulation # 12. - A pKa buffered vitamin C composition of the present invention is formed by mixing, such as in a ribbon blender, an alkalizing base composition (numerous formulations of which are disclosed in detail in this disclosure) and vitamin C. The vitamin C can be powder or compressible-granular calcium ascorbate or ascorbic acid. The base alkalizer composition can be approximately 24% to 40% (or approximately 24%) by weight and the ascorbic acid or calcium ascorbate approximately 60% to 76% (or approximately 76%) of the vitamin C composition. The vitamin C composition thereby formed is packaged, for example, in fifty or twenty-five kilogram packages. The packages are delivered to a tablet or capsule manufacturer who puts the composition into tablet or capsule form as would be known and in sizes as would also be known by those skilled in the art. For tablets, a minimum of 240 milligrams of base composition to 500 milligrams of vitamin C may be included. While a preferred embodiment is 500 milligrams of vitamin C, it can be buffered just as well pursuant to this invention at 200 milligrams of vitamin C. Further, smaller tablets of 80 milligrams of base to 200 milligrams of vitamin C are also within the scope of the invention.
- The alkalizing compositions may be produced as a granulated, agglomerate compound by milling, blending and spray drying the ingredients in a Shugi agglomerating system. The Shugi agglomerating system is a commercially available system that has been designed to agglomerate minerals to USP and pharmaceutical standards. It is designed to properly mix and agglomerate various ingredients with different molecular weights into a uniform granule.
- The ingredients of the alkalizing composition can be first milled to a fine powder. The fine powder is then heated to thirty degrees to thirty-nine degrees Centigrade and pressure sprayed into an environment having a relative humidity of from about 9.0% to about 15.0%. The fine powder is then sprayed with a solution of gum acacia to achieve a uniform granule that is free-flowing, non-dusting, and highly compressible. Gum acacia aids in providing uniform finished granules.
- The resulting granulated alkalizing compositions can have a pH in the range of from about 5.0 to about 13.0, from about 6.5 to about 11.5, or from about 8.0 to about 10.0.
- The following alkalizing base compositions are suitable for use in the formulations and methods disclosed herein:
-
Formulation # 1Ingredients % by weight calcium carbonate 79.08% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99 dicalcium phosphate 1.40 - In one embodiment, the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium hydroxide; and from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight dicalcium phosphate.
-
Formulation # 2Ingredients % by weight calcium carbonate 84.00% potassium hydroxide 4.50 gum acacia 4.50 potassium bicarbonate 2.90 dicalcium phosphate 2.90 tricalcium phosphate 1.20 - In another embodiment, the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 75% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight dicalcium phosphate; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight tricalcium phosphate; and from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium bicarbonate; and from about 0.01% to about 10%, from 0.01% to about 8%, from 0.01% to about 6%, or from about 1.0% to about 5% by weight gum acacia.
-
Formulation # 3Ingredients % by weight calcium carbonate 88.08% potassium hydroxide 6.00 potassium bicarbonate 4.00 dicalcium phosphate 1.92 - In yet another embodiment, the alkalizing composition comprises: from about 50% to about 99%, from about 60% to about 95%, or from about 70% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 2% to about 8%, or from about 4% to about 7% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium bicarbonate; and from about 0.01% to about 5%, from about 0.01% to about 4%, or from about 0.01% to about 3% by weight dicalcium phosphate.
-
Formulation # 4Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99 - In another embodiment, the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia, and from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight potassium hydroxide.
-
Formulation # 5Ingredients % by weight calcium carbonate 82.00% sodium hydroxide 7.50 dicalcium phosphate 2.00 potassium hydroxide 2.05 potassium bicarbonate 1.65 gum acacia 4.80 -
Formulation # 6Ingredients % by weight calcium carbonate 82.00% sodium hydroxide 7.50 dicalcium phosphate 2.00 potassium hydroxide 2.00 potassium bicarbonate 3.00 gum acacia 4.00 - In a further embodiment, the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 2% to about 10%, or from about 5% to about 9% by weight sodium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 4% by weight dicalcium phosphate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 4% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 4% by weight potassium bicarbonate; from about 0.01% to about 10%, from about 0.1% to about 8%, or from about 0.01% to about 6% by weight gum acacia.
-
Formulation # 7Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.77 potassium hydroxide 1.98 - In accordance with another embodiment, the alkalizing composition may comprise from about 50% to about 99%, from about 60% to about 95%, or from about 70% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 4% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia; and from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium hydroxide.
-
Formulation # 8Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 gum acacia 4.77 DC ascorbic acid 3.00 dicalcium phosphate 2.00 potassium hydroxide 1.98 -
Formulation # 9Ingredients % by weight calcium carbonate 79.40% magnesium hydroxide 7.20 DC ascorbic acid 4.77 gum acacia 3.00 dicalcium phosphate 2.00 potassium hydroxide 1.98 potassium bicarbonate 1.65 - In another embodiment, the alkalizing composition comprises from about 50% to about 99% by weight, from about 60% to about 95% by weight, or from about 70% to about 90% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10% by weight, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 5% by weight ascorbic acid; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight dicalcium phosphate; and from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium hydroxide.
-
Formulation # 10Ingredients % by weight calcium carbonate 82.50% magnesium hydroxide 7.00 dicalcium phosphate 2.00 potassium hydroxide 2.00 potassium bicarbonate 1.50 gum acacia 5.00 - In yet a further embodiment, the alkalizing composition comprises from about 50% to about 99%, from about 60% to about 90%, or from about 70% to about 85% by weight calcium carbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 5% to about 8% by weight magnesium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 5% by weight dicalcium phosphate; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium hydroxide; from about 0.01% to about 10%, from about 0.01% to about 6%, or from about 0.01% to about 4% by weight potassium bicarbonate; from about 0.01% to about 10%, from about 0.01% to about 8%, or from about 0.01% to about 6% by weight gum acacia. The alkalizing composition may further comprise a vitamin, such as ascorbic acid.
- In another embodiment, the alkalizing composition can comprise calcium carbonate, magnesium hydroxide, DC ascorbic acid, gum acacia, potassium hydroxide, and dicalcium phosphate. Optionally, the alkalizing composition can contain vitamin D3.
- The following additional formulations may be used to produce suitable alkalizing compositions for use in connection with the methods and vitamin C compositions disclosed herein:
-
Formulation # 11Ingredients % by weight calcium carbonate 80.48% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99 -
Formulation # 12Ingredients % by weight calcium carbonate 79.08% magnesium hydroxide 7.77 DC ascorbic acid 5.00 gum acacia 4.76 potassium hydroxide 1.99 dicalcium phosphate 1.40 - In one embodiment, the alkalizing composition can comprise calcium carbonate, magnesium hydroxide, DC ascorbic acid, gum acacia, potassium hydroxide, and optionally vitamin D3.
- Anticipated functioning of calcium ascorbate and each of formulations #1-#12, as discussed above, of the present invention in the user's stomach are illustrated in the chart of the drawing figures. Each of the charts of the drawing figures shows test results for the neutralization of 100 grams solution of 0.015 M hydrochloric acid (HCL) (pH 2.00) by 300 milligrams of a respective formulation sample.
- Referring to the drawing figures, the present invention, due to its high pKa, immediately neutralizes the stomach acid to a pH of 7.0 in one minute and a pH of 7.5 after eight minutes. Some people receive an added benefit because the temporary chelating of calcium supplied by the invention temporarily protects vitamin C (ascorbate ion) from oxidation to dehyroascorbic acid and subsequent rapid oxidative degradation in the duodenum. Additionally, some individuals absorb only a few milligrams of vitamin C (ascorbate) out of each gram of ascorbic acid ingested, and thus they will benefit from vitamin C chelated as calcium, magnesium or potassium ascorbate.
- From the foregoing detailed description, it will be evident that there are a number of changes, adaptations and modifications of the present invention which come within the province of those skilled in the art. For example, the present invention includes all of the formulations disclosed herein. Further, the scope of the invention includes any combination of the elements from the different species, formulations or embodiments disclosed herein, as well as subassemblies, assemblies, and methods of using and making thereof, and combinations of the various percentage ranges. It is intended that all such variations not departing from the spirit of the invention be considered as within the scope thereof
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/506,262 US20150024064A1 (en) | 2007-02-14 | 2014-10-03 | pKa Buffered Vitamin C Composition and Method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/675,062 US8853262B2 (en) | 2007-02-14 | 2007-02-14 | pKa buffered vitamin C composition and method |
US14/506,262 US20150024064A1 (en) | 2007-02-14 | 2014-10-03 | pKa Buffered Vitamin C Composition and Method |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/675,062 Continuation US8853262B2 (en) | 2007-02-14 | 2007-02-14 | pKa buffered vitamin C composition and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150024064A1 true US20150024064A1 (en) | 2015-01-22 |
Family
ID=39686031
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/675,062 Expired - Fee Related US8853262B2 (en) | 2007-02-14 | 2007-02-14 | pKa buffered vitamin C composition and method |
US14/506,262 Abandoned US20150024064A1 (en) | 2007-02-14 | 2014-10-03 | pKa Buffered Vitamin C Composition and Method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/675,062 Expired - Fee Related US8853262B2 (en) | 2007-02-14 | 2007-02-14 | pKa buffered vitamin C composition and method |
Country Status (2)
Country | Link |
---|---|
US (2) | US8853262B2 (en) |
WO (1) | WO2008100874A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190015449A1 (en) * | 2017-07-17 | 2019-01-17 | Dr. Marlowe's Weight Loss Institute, P.L.L.C. | Supplement for treating side effects of medications which cause metabolic acidosis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853787A (en) * | 1995-12-22 | 1998-12-29 | Tamer International | Method for reducing coffee acidity |
WO2001022836A1 (en) * | 1999-09-30 | 2001-04-05 | The Procter & Gamble Company | Method for extending the flavor shelf life of aqueous compositions flavored with moisture and acid sensitive flavors and flavor compositions having extended flavor shelf lives |
US6783781B2 (en) * | 2000-11-29 | 2004-08-31 | Douglas G. Mann | Method of stabilizing fruit-concentrate powders |
US8808774B2 (en) * | 2005-06-20 | 2014-08-19 | Scientific Food Solutions, Llc | pKa buffered flavor enhanced reduced moisture fruits and vegetables |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2836540A (en) * | 1952-03-19 | 1958-05-27 | Hardt Foundation | Pharmaceutical antacid composition |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
US20060217385A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
US20070248542A1 (en) * | 2006-04-24 | 2007-10-25 | Bodybio, Inc. | Devices and methods for individualized detection of nutrient imbalance via olfactory system |
-
2007
- 2007-02-14 US US11/675,062 patent/US8853262B2/en not_active Expired - Fee Related
-
2008
- 2008-02-11 WO PCT/US2008/053628 patent/WO2008100874A2/en active Application Filing
-
2014
- 2014-10-03 US US14/506,262 patent/US20150024064A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5853787A (en) * | 1995-12-22 | 1998-12-29 | Tamer International | Method for reducing coffee acidity |
WO2001022836A1 (en) * | 1999-09-30 | 2001-04-05 | The Procter & Gamble Company | Method for extending the flavor shelf life of aqueous compositions flavored with moisture and acid sensitive flavors and flavor compositions having extended flavor shelf lives |
US6783781B2 (en) * | 2000-11-29 | 2004-08-31 | Douglas G. Mann | Method of stabilizing fruit-concentrate powders |
US8808774B2 (en) * | 2005-06-20 | 2014-08-19 | Scientific Food Solutions, Llc | pKa buffered flavor enhanced reduced moisture fruits and vegetables |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190015449A1 (en) * | 2017-07-17 | 2019-01-17 | Dr. Marlowe's Weight Loss Institute, P.L.L.C. | Supplement for treating side effects of medications which cause metabolic acidosis |
US10342824B2 (en) * | 2017-07-17 | 2019-07-09 | Dr. Marlowe's Weight Loss Institute, P.L.L.C. | Supplement for treating side effects of medications which cause metabolic acidosis |
Also Published As
Publication number | Publication date |
---|---|
US20080193556A1 (en) | 2008-08-14 |
WO2008100874A2 (en) | 2008-08-21 |
US8853262B2 (en) | 2014-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0732920B1 (en) | Therapeutic agents containing thyroid hormones | |
TWI410258B (en) | Improved stability in vitamin and mineral supplements | |
CN101001611B (en) | Particulate comprising a calcium-containing compound and a sugar alcohol | |
CA2072513C (en) | Lozenge or chewable tablet | |
AU2012296358B2 (en) | Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system | |
CZ20002391A3 (en) | Flash-melt oral dosage formulation and process for preparing thereof | |
US20130052278A1 (en) | Quick dissolve nutritional powder | |
KR20070111478A (en) | Compositions and methods for nutrition supplementation | |
US20100190739A1 (en) | Rapidly Dissolving Vitamin Formulation and Methods of Using the Same | |
JP2002530322A (en) | Taste masking rapid release coating system | |
CN101277721B (en) | Orally disintegrating tablet | |
JP2002530322A5 (en) | ||
US6447807B1 (en) | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery | |
EP2420147A1 (en) | Nutritional supplement compositon | |
US5665782A (en) | Hydrolyzed gelatin as a flavor enhancer in a chewable table | |
US20150024064A1 (en) | pKa Buffered Vitamin C Composition and Method | |
US7189416B2 (en) | Method for stable and controlled delivery of (-)-hydroxycitric acid | |
GB2195245A (en) | Sustained release fluoride composition | |
JP2002029964A (en) | Solid medicine composition | |
US7097859B2 (en) | Indium supplement compositions and methods therefor | |
US6605306B1 (en) | Food supplement formulation | |
US20160143845A1 (en) | Quick dissolve nutritional powder | |
US5399356A (en) | Process for making solid dose forms containing bismuth | |
CA2184361C (en) | Solid dose forms containing bismuth | |
CN107875170B (en) | Calcium carbonate-containing effervescent agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NUTRA PRODUCTS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCIENTIFIC FOOD SOLUTIONS, LLC;REEL/FRAME:033884/0645 Effective date: 20140925 Owner name: SCIENTIFIC FOOD SOLUTIONS, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FALKENBERG, RICKY L.;ARCHIBALD, HAROLD L.;REEL/FRAME:033884/0547 Effective date: 20070515 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: VIGOUR LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUTRA PRODUCTS, INC.;REEL/FRAME:046873/0384 Effective date: 20180913 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |